Verve Therapeutics (VERV) Stock Forecast & Price Target

Compare

670 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VERV Analyst Ratings

Strong Buy

9 Buy

1 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Verve

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VERV Stock 12 Month Forecast

Average Price Target

$24.00

▲(318.85%Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Verve Therapeutics in the last 3 months. The average price target is $24.00 with a high forecast of $39.00 and a low forecast of $15.00. The average price target represents a 318.85% change from the last price of $5.73.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","40":"$40","12.25":"$12.25","21.5":"$21.5","30.75":"$30.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$39.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,12.25,21.5,30.75,40],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.5,8.076923076923077,10.653846153846153,13.230769230769232,15.807692307692308,18.384615384615387,20.961538461538463,23.53846153846154,26.115384615384617,28.692307692307693,31.26923076923077,33.84615384615385,36.42307692307693,{"y":39,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.5,6.923076923076923,8.346153846153847,9.76923076923077,11.192307692307693,12.615384615384617,14.038461538461538,15.461538461538462,16.884615384615387,18.307692307692307,19.730769230769234,21.153846153846153,22.576923076923077,{"y":24,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.5,6.230769230769231,6.961538461538462,7.692307692307692,8.423076923076923,9.153846153846153,9.884615384615383,10.615384615384615,11.346153846153847,12.076923076923077,12.807692307692307,13.538461538461538,14.269230769230768,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.58,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.21,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.79,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.73,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.93,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.16,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.64,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.61,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.33,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$39.00

Average Price Target$24.00

Lowest Price Target$15.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

Hold

4.71%

Upside

Reiterated

06/06/25

Verve Therapeutics' stock is buoyed by strong technical momentum, despite challenges in financial performance and valuation. The company's robust balance sheet offers some financial stability, but its unprofitability and negative P/E ratio are significant concerns. Investors should be cautious of the high-risk profile due to the negative margins and volatile nature of the biotechnology sector.

Whitney IjemCanaccord Genuity

Canaccord Genuity

$39

Buy

580.63%

Upside

Reiterated

05/23/25

Canaccord Genuity Reaffirms Their Buy Rating on Verve Therapeutics (VERV)

Mitchell KapoorH.C. Wainwright

H.C. Wainwright

$25

Buy

336.30%

Upside

Reiterated

05/19/25

Verve Therapeutics (VERV) Gets a Buy from H.C. Wainwright

Kostas BiliourisBMO Capital

BMO Capital

$30→$20

Buy

249.04%

Upside

Reiterated

05/15/25

Post 1Q: Strong '102 Data Set the Stage for Positive Data/Opt-in Updates in 2H

Seamus FernandezGuggenheim

Guggenheim

$24

Buy

318.85%

Upside

Reiterated

05/14/25

Analysts' Top Healthcare Picks: ADC Therapeutics (ADCT), Verve Therapeutics (VERV)

Myles MinterWilliam Blair

William Blair

―

Buy

―

Reiterated

05/14/25

William Blair Remains a Buy on Verve Therapeutics (VERV)

Cory Jubinville, PhDLifeSci Capital

LifeSci Capital

$25

Buy

336.30%

Upside

Reiterated

05/14/25

Buy Rating for Verve Therapeutics: Promising Phase 1 Data and Strong Financial Position

Luca IssiRBC Capital

RBC Capital

$15

Buy

161.78%

Upside

Reiterated

05/14/25

Analysts Are Bullish on Top Healthcare Stocks: Verve Therapeutics (VERV), Aardvark Therapeutics, Inc. (AARD)

Eun YangJefferies

Jefferies

$28

Buy

388.66%

Upside

Reiterated

04/15/25

Jefferies reiterates Buy Rating on Verve Therapeutics (VERV)Jefferies analyst Eun Yang reiterated a Buy rating and $28.00 price target on Verve Therapeutics (NASDAQ: VERV)

Eric JosephJ.P. Morgan

J.P. Morgan

$19→$16

Hold

179.23%

Upside

Reiterated

04/15/25

J.P. Morgan Sticks to Their Hold Rating for Verve Therapeutics (VERV)

Rick BienkowskiCantor Fitzgerald

Cantor Fitzgerald

―

Buy

―

Upgraded

04/15/25

Verve Therapeutics upgraded to Overweight from Neutral at Cantor FitzgeraldVerve Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald

Dae Gon HaStifel Nicolaus

Stifel Nicolaus

―

Buy

―

Reiterated

12/10/24

Stifel Nicolaus Sticks to Their Buy Rating for Verve Therapeutics (VERV)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

Hold

4.71%

Upside

Reiterated

06/06/25

Whitney IjemCanaccord Genuity

Canaccord Genuity

$39

Buy

580.63%

Upside

Reiterated

05/23/25

Canaccord Genuity Reaffirms Their Buy Rating on Verve Therapeutics (VERV)

Mitchell KapoorH.C. Wainwright

H.C. Wainwright

$25

Buy

336.30%

Upside

Reiterated

05/19/25

Verve Therapeutics (VERV) Gets a Buy from H.C. Wainwright

Kostas BiliourisBMO Capital

BMO Capital

$30→$20

Buy

249.04%

Upside

Reiterated

05/15/25

Post 1Q: Strong '102 Data Set the Stage for Positive Data/Opt-in Updates in 2H

Seamus FernandezGuggenheim

Guggenheim

$24

Buy

318.85%

Upside

Reiterated

05/14/25

Analysts' Top Healthcare Picks: ADC Therapeutics (ADCT), Verve Therapeutics (VERV)

Myles MinterWilliam Blair

William Blair

―

Buy

―

Reiterated

05/14/25

William Blair Remains a Buy on Verve Therapeutics (VERV)

Cory Jubinville, PhDLifeSci Capital

LifeSci Capital

$25

Buy

336.30%

Upside

Reiterated

05/14/25

Buy Rating for Verve Therapeutics: Promising Phase 1 Data and Strong Financial Position

Luca IssiRBC Capital

RBC Capital

$15

Buy

161.78%

Upside

Reiterated

05/14/25

Analysts Are Bullish on Top Healthcare Stocks: Verve Therapeutics (VERV), Aardvark Therapeutics, Inc. (AARD)

Eun YangJefferies

Jefferies

$28

Buy

388.66%

Upside

Reiterated

04/15/25

Jefferies reiterates Buy Rating on Verve Therapeutics (VERV)Jefferies analyst Eun Yang reiterated a Buy rating and $28.00 price target on Verve Therapeutics (NASDAQ: VERV)

Eric JosephJ.P. Morgan

J.P. Morgan

$19→$16

Hold

179.23%

Upside

Reiterated

04/15/25

J.P. Morgan Sticks to Their Hold Rating for Verve Therapeutics (VERV)

Rick BienkowskiCantor Fitzgerald

Cantor Fitzgerald

―

Buy

―

Upgraded

04/15/25

Verve Therapeutics upgraded to Overweight from Neutral at Cantor FitzgeraldVerve Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald

Dae Gon HaStifel Nicolaus

Stifel Nicolaus

―

Buy

―

Reiterated

12/10/24

Stifel Nicolaus Sticks to Their Buy Rating for Verve Therapeutics (VERV)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Verve Therapeutics

1 Month

xxx

Success Rate

6/12 ratings generated profit

Average Return

-3.28%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -3.28% per trade.

3 Months

xxx

Success Rate

6/12 ratings generated profit

Average Return

-7.14%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -7.14% per trade.

1 Year

Kostas BiliourisBMO Capital

Success Rate

3/17 ratings generated profit

Average Return

-31.42%

reiterated a buy rating 23 days ago

Copying Kostas Biliouris's trades and holding each position for 1 Year would result in 17.65% of your transactions generating a profit, with an average return of -31.42% per trade.

2 Years

xxx

Success Rate

2/12 ratings generated profit

Average Return

-30.14%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 16.67% of your transactions generating a profit, with an average return of -30.14% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VERV Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VERV has received 22 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. VERV average Analyst price target in the past 3 months is 24.00.

Each month's total comprises the sum of three months' worth of ratings.

VERV Financial Forecast

VERV Earnings Forecast

Next quarter’s earnings estimate for VERV is -$0.67 with a range of -$0.82 to -$0.54. The previous quarter’s EPS was -$0.35. VERV beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year VERV has Outperformed its overall industry.

VERV Sales Forecast

Next quarter’s sales forecast for VERV is $4.34M with a range of $0.00 to $13.08M. The previous quarter’s sales results were $32.98M. VERV beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year VERV has Outperformed its overall industry.

VERV Stock Forecast FAQ

What is VERV’s average 12-month price target, according to analysts?

Based on analyst ratings, Verve Therapeutics’s 12-month average price target is 24.00.

What is VERV’s upside potential, based on the analysts’ average price target?

Verve Therapeutics has 318.85% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VERV a Buy, Sell or Hold?

Verve Therapeutics has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.

What is Verve Therapeutics’s price target?

The average price target for Verve Therapeutics is 24.00. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $39.00 ,the lowest forecast is $15.00. The average price target represents 318.85% Increase from the current price of $5.73.

What do analysts say about Verve Therapeutics?

Verve Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of VERV?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Verve Therapeutics (VERV) Stock Forecast & Price Target

VERV Analyst Ratings

VERV Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Verve Therapeutics

VERV Analyst Recommendation Trends

VERV Financial Forecast

VERV Earnings Forecast

VERV Sales Forecast

VERV Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts